Ahirwar et al.277 found that Slit2, a tumor suppressor, could regulate TAMs in the breast cancer tumor microenvironment, including increasing the recruitment of M1-type TAMs and increasing their phagocytosis of tumor cells, which demonstrated that Slit2, a tumor suppressor, could effectively play an antitumor role and revealed the potential of Slit2 as an immunotherapeutic agent. Here, SLIT2 is linked to breast carcinoma.